Aldeyra dry eye disease candidate hit by FDA delay amid shifting agency guidance, biotech says
Aldeyra dry eye disease candidate hit by FDA delay amid shifting agency guidance, biotech says
Body unavailable. Use the original source.
Aldeyra dry eye disease candidate hit by FDA delay amid shifting agency guidance, biotech says
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.